1 2	KAMALA D. HARRIS Attorney General of California KENT D. HARRIS	
3	Supervising Deputy Attorney General	
	Leslie A. Burgermyer Deputy Attorney General	
4	State Bar No. 117576 1300 I Street, Suite 125	
5	P.O. Box 944255 Sacramento, CA 94244-2550	
6	Telephone: (916) 324-5337 Facsimile: (916) 327-8643	
7	E-mail: Leslie.Burgermyer@doj.ca.gov Attorneys for Complainant	
8	BEFORE THE	
9	BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS	
10	STATE OF CALIFO	
11	In the Matter of the Accusation Against:	Case No. 5533
12	KAISER PERMANENTE CORP., DBA KAISER PERMANENTE PHARMACY #833	Case No. 3333
13	3800 Dale Rd.	ACCUSATION
14	P. O. Box 577680 Modesto, CA 95357	ACCUSATION
15	Pharmacy Permit Number PHY 46384	
16	And	
17	DARIN L. SISE, RPH	
18	Pharmacist-In-Charge P. O. Box 578987	
19	Modesto, CA 95357	
20	Pharmacist Permit Number RPH 43429	
21	Respondents.	
22	Complainant alleges:	
23	<u>PARTIES</u>	
24	1. Virginia Herold ("Complainant") brings this Accusation solely in her official	
25	capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.	
26	2. On or about April 17, 2003, the Board of Pharmacy, Department of Consumer	
27	Affairs, ("Board") issued Pharmacy Permit Number PHY 46384 to Kaiser Permanente Corp.,	
28	doing business as Kaiser Permanente Pharmacy #833, ("R	Respondent Kaiser"). The Pharmacy
	1	

2

ACCUSATION

1	any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.	
2	STATUTORY PROVISIONS	
3	8. Code section 4301 states, in pertinent part:	
4	(j) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.	
5	(o) Violating or attempting to violate, directly or indirectly, or assisting in or	
6	abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing	
7 8	federal regulatory agency.	
9	9. Section 4022 of the Code states	
10	Dangerous drug" means any drug or device unsafe for self-use in humans	
11	or animals, and includes the following:	
12	(a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without prescription," "Rx only," or words of similar import.	
13	(c) Any other drug that by federal or state law can be lawfully dispensed only on prescription or furnished pursuant to Section 4006.	
14	only on prescription of furnished pursuant to section 4000.	
15	10. Code section 4081 states, in pertinent part:	
16	(a) All records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during	
17	business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall	
18	be kept by every manufacturer, wholesaler, third-party logistics provider, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian,	
19	laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division	
20	2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions	
21	Code who maintains a stock of dangerous drugs or dangerous devices.	
22	11. Code section 4105 states:	
23	(a) All records or other documentation of the acquisition and disposition of dangerous drugs and dangerous devices by any entity licensed by the board shall be	
24	retained on the licensed premises in a readily retrievable form.	
25	(b) The licensee may remove the original records or documentation from the licensed premises on a temporary basis for license-related purposes. However, a	
26	duplicate set of those records or other documentation shall be retained on the licen premises.	
27_	(c) The records required by this section shall be retained on the licensed	
28	premises for a period of three years from the date of making.	

the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

BACKGROUND

- 17. On or about December 6, 2013, Respondent Sise discovered a low inventory of Hydrocodone/APAP 10/325 mg on Respondent Kaiser's drug shelf; the shelf had been full the previous night.
- 18. From on or about December 7 through 9, 2013, Respondent Kaiser's internal investigation and surveillance disclosed that janitor A.G. was stealing the Hydrocodone/APAP 10/325 mg from the shelves of Respondent Kaiser. A.G. confessed he had been stealing the drug for the past six months for self-use and for supplying to his friends. A.G. was terminated on or about January 6, 2014. Respondents' internal investigation revealed a shortage of 64,460 tablets of Hydrocodone/ APAP 10/325mg for the period of June 27, 2013, to December 10, 2013.
- On or about January 9, 2014, Respondents notified the Board that Respondent Pharmacy had experienced a loss of 64,460 tablets of Hydrocodone/APAP 10/325mg. On or about May 7, 2014, Respondent Kaiser submitted an amended report of loss of controlled substances indicating the amended loss of 77,115 tablets of Hydrocodone/APAP 10/325mg.
- 20. From on or about January 14, 2014, through May 13, 2015, the Board's assigned inspector conducted an investigation of Respondents reported drug loss.
- 21. On or about August 27, 2014, the inspector received Respondent's acquisition and disposition records for Hydrocodone/APAP 10/325mg for the period of March 17, 2013 to December 9, 2103. Based upon those records, the inspector's audit results concluded that Respondents' actual shortage of Hydrocodone/APAP 10/325 mg was 75,266 tablets.
- 22. On or about May 13, 2015, the Board issued a notice of non-compliance to Respondent Kaiser and Respondent Sise due to their failure to maintain their dangerous drugs in a safe and secure manner and failure to have records of disposition to account for the inventory shortage of 75,266 tablets of Hydrocodone/APAP 10/325 mg.

27

/// 28

 28^{-}

FIRST CAUSE FOR DISCIPLINE

(Failure to Maintain Dangerous Drugs in Safe and Secure Manner)

- 23. Respondent Kaiser is subject to disciplinary action under Code sections 4300 and 4301, subdivisions (j) and (o), in conjunction with California Code of Regulations, title 16, section 1714, subdivision (b), in that Respondent Kaiser failed to maintain its facilities, space, fixtures, and equipment so that drugs in its stock were safely and properly prepared, maintained, secured and distributed. Respondent Kaiser's failures resulted in the loss of 75,266 tablets of the dangerous drug Hydrocodone/ APAP 10/325mg as set forth in paragraphs 17 through 22, above, incorporated herein by reference.
- 24. Respondent Sise, the Pharmacist-in-Charge, is subject to disciplinary action sections 4300 and 4300.1, subdivisions (j) and (o), in conjunction with California Code of Regulations, title 16, section 1714, subdivision (d), in that Respondent Sise failed to secure the prescription department of Respondent Kaiser and failed to provide for the effective control against theft or diversion of dangerous drugs resulting in the loss of 75,266 tablets of Hydrocodone/APAP 10/325mg as set forth in paragraphs 17 through 22, above, incorporated herein by reference.

SECOND CAUSE FOR DISCIPLINE

(Failure to Maintain Records of Disposition of Dangerous Drugs)

25. Respondent Kaiser and Respondent Sise, the Pharmacist-in-Charge, are subject to disciplinary action under Code sections 4300 and 4300.1, subdivisions (j) and (o), in conjunction with Code sections 4081, subdivision (a), and 4105, in that they failed to maintain and preserve all records of acquisition, disposition, and current inventory of dangerous drugs which resulted in their failure to have records of disposition to account for an inventory shortage of 75,266 tablets of the dangerous drug Hydrocodone/APAP 10/325mg as set forth in paragraphs 17 through 22, above, incorporated herein by reference.

DISCIPLINARY CONSIDERATION

26. In determining the level of discipline to be imposed on Respondent Kaiser, Complainant respectfully requests that the following be considered:

1	27. On or about February 8, 2011, pursuant to Code sections 4314 and 4301, subdivision	
2	(o), and California Code of Regulations ("CCR"), title 16, section 1775, the Board issued	
3	Citation No. 2009 44600 against Respondent Kaiser for violating CCR, title 16, section 1714,	
4	subdivision (b), in that from June 27, 2008, through May 31, 2010, Respondent could not account	
5	for 7,627 tablets of Zolpidem 10mg. A civil penalty was not imposed.	
6	<u>PRAYER</u>	
7	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged	
8	and that following the hearing, the Board of Pharmacy issue a decision:	
9	1. Revoking or suspending Pharmacy Permit Number PHY 46384 issued to Kaiser	
10	Permanente Corp., doing business as Kaiser Permanente Pharmacy #833;	
11	2. Revoking or suspending Pharmacy License Number RPH 43429 issued to Darin L.	
12	Sise, Pharmacist-In-Charge for Kaiser Permanente Corp., doing business as Kaiser Permanente	
13	Pharmacy #833;	
14	3. Ordering Kaiser Permanente Corp., doing business as Kaiser Permanente Pharmacy	
15	#833 and Darin L. Sise, RPH, to pay the Board of Pharmacy the reasonable costs of the	
16	investigation and enforcement of this case, pursuant to Business and Professions Code section	
17	125.3; and	
18	4. Taking such other and further action as deemed necessary and proper.	
19 20	DATED: 2/20/16 Prague Shedel	
21	VIRGINIA HEROLD	
22	Executive Officer Board of Pharmacy Department of Consumer Afficial	
23	Department of Consumer Affairs State of California	
24	Complainant	
25	SA201510443 / 12119193.doc	
26		
27		
28		